J
Julien Taieb
Researcher at University of Paris
Publications - 482
Citations - 11958
Julien Taieb is an academic researcher from University of Paris. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 50, co-authored 409 publications receiving 8679 citations. Previous affiliations of Julien Taieb include Paris Descartes University & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Exploring the best treatment options for BRAF-mutant metastatic colon cancer
TL;DR: This review highlights still-emerging strategies that could be deployed to combat BRAF-mt mCRC, including triplet chemotherapy plus available biologic agents, rationally derived combinations of targeted agents and immunotherapy.
Journal ArticleDOI
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.
Julien Taieb,Andreas Jung,Andreas Jung,Andrea Sartore-Bianchi,Marc Peeters,Jenny Seligmann,Aziz Zaanan,Peter Burdon,Clara Montagut,Pierre Laurent-Puig +9 more
TL;DR: New biomarker-led treatment strategies in addition to anti-epidermal growth factor receptor and anti-angiogenetic treatments are being explored and recommended treatment strategies according to the biomarker status are provided.
Journal ArticleDOI
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
Dirk Arnold,Gerald W. Prager,Antonio Quintela,Alexander Stein,S. Moreno Vera,Nadjat Mounedji,Julien Taieb +6 more
TL;DR: Findings support the introduction of an approved agent such as trifluridine/tipiracil or regorafenib beyond the second line before any rechallenge in patients with metastatic colorectal cancer who have failed second-line treatment.
Journal ArticleDOI
Ethanol-induced inhibition of cytokine release and protein degranulation in human neutrophils.
Julien Taieb,Charlotte Delarche,Frédéric Ethuin,Saphia Selloum,Thierry Poynard,Marie-Anne Gougerot-Pocidalo,Sylvie Chollet-Martin +6 more
TL;DR: It is suggested that ethanol may modulate three major cytokines involved in alcoholic liver diseases, IL‐8, TNF‐α, and HGF, via three different mechanisms.
Journal ArticleDOI
Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo.
TL;DR: The paradigmatic KIT, PDGFR, ABL tyrosine kinase inhibitor imatinib mesylate (STI571/Gleevec), known to induce potent antitumor effects in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors, acts on nonmalignant hematopoietic cells.